0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Subcutaneous Unfractionated Heparin vs Low-Molecular-Weight Heparin for Acute Thromboembolic Disease:  Issues of Efficacy and Cost

Jeffrey L. Carson, MD
JAMA. 2006;296(8):991-993. doi:10.1001/jama.296.8.991.
Text Size: A A A
Published online

Extract

Since 1960, when Barrett and Jordan established that anticoagulation reduced the risk of death in patients with pulmonary embolism,1 heparin has been the treatment of choice for thromboembolic disease. Heparin was initially administered by intravenous bolus every 4 hours until clinical trials showed that unfractionated intravenous infusion was associated with less bleeding.2,3 Unfractionated heparin was administered by intravenous infusion and the activated partial thromboplastin time (aPTT) was monitored to maintain a level between 1.5 to 2.5 times control. It was common practice to begin treatment with a loading dose of 5000 units and 1000 units per hour of infusion. Clinical experience revealed that many patients had subtherapeutic aPTT levels for more than 24 hours and were more likely to develop recurrent thromboembolism.4,5 Today, the standard of care is to use a weight-based algorithm6 or other heparin protocols7 that quickly achieve therapeutic targets for the aPTT.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 6

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
Thromboembolism or Acute Pulmonary Embolism

brightcove.createExperiences();